BioSpace News Archive

Alvotech, a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced that it has reached settlement agreements with Johnson & Johnson in Japan, Canada and in the European Economic Area for AVT04, a biosimilar to Stelara®.

Quince Therapeutics, Inc. announced the appointment of Rajiv Patni, M.D., a biopharma industry veteran and global product development expert, to the company’s Board of Directors.

Repare Therapeutics Inc. announced the first patient has been dosed in the Company’s Phase 1 LIONS clinical trial evaluating RP-1664, a potential first-in-class, highly selective, oral polo-like kinase 4 inhibitor, for the monotherapy treatment of adult and adolescent patients enriched for TRIM37-high solid tumors.

Arbutus Biopharma Corporation announced that it has scheduled its fourth quarter and year end 2023 financial results and corporate update for Thursday, February 29, 2024.

Valneva SE a specialty vaccine company, reported its revenue and cash balance for the full year 2023 and provided first full year 2024 sales and R&D expense guidance.

Verona Pharma plc announces that it will report its financial results for the fourth quarter and full year ended December 31, 2023 on Thursday, February 29, 2024 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update.

Pharus Diagnostics announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma.

Nyxoah SA announced that the Company will release financial results for the fourth quarter and financial year 2023 on Tuesday, March 5, 2024, after market close.

GE HealthCare Technologies Inc. announced the launch of a secondary underwritten public offering of 13,000,000 shares of its common stock.

Avidity Biosciences, Inc. announced that the company will be presenting multiple posters from all three clinical development programs in rare muscle diseases, including new AOC 1001 long-term efficacy and safety data from the MARINA open-label extension trial in people living with myotonic dystrophy type 1 at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida.